MCAM and exocrine pancreatic carcinoma: The clinical benefit from VEGF-targeted therapies is always compromised during continued treatment with anti-VEGF antibodies, such as Bevacizumab in pancreatic carcinoma.110,225,226 Thus, our findings indicate the possibility that the clinical efficacy of anti-VEGF therapy can be augmented by targeting CD146 treatment in the future.